Litcius/Paper detail

Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case–control study

Sara Y. Tartof, Jeff Slezak, Laura Puzniak, Vennis Hong, Timothy B. Frankland, Bradley K. Ackerson, Fagen Xie, Harpreet S. Takhar, Oluwaseye Ayoola Ogun, Sarah Simmons, Joann M. Zamparo, Srinivas Rao Valluri, Luis Jódar, John M. McLaughlin

2023The Lancet Respiratory Medicine77 citationsDOIOpen Access PDF

Topics & Concepts

MedicineCoronavirus disease 2019 (COVID-19)Bivalent (engine)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologyFamily medicineInternal medicineInfectious disease (medical specialty)DiseaseMetalOrganic chemistryChemistryOutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesImmune responses and vaccinations
Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case–control study | Litcius